ArticleThe New England journal of medicine2019
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- HMGB1 blockade attenuates cardiac injury induced by radiotherapy combined with PD-1 inhibitor while maintaining the anti-tumor efficacy.Apoptosis : an international journal on programmed cell death · 2026Article
- A 7-gene expression signature predicts immune microenvironment remodeling and neoadjuvant chemo-immunotherapy response in lung squamous cell carcinoma.Frontiers in immunology · 2026Article
- Efficacy and safety of induction chemoimmunotherapy in older patients with unresectable stage III NSCLC: a real-world multicenter study.Therapeutic advances in medical oncology · 2026Article
- [Combination of Radiotherapy and Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer: Clinical Progress Advances and Future Directions].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer.Scientific reports · 2025Article
- A Single-arm, Open-label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer.Recent patents on anti-cancer drug discovery · 2025Article
- PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.Cancer medicine · 2024Article
- A retrospective comparison of induction chemoimmunotherapy versus chemotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in stage III non-small cell lung cancer.Frontiers in oncology · 2024Article
- Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.Cancer science · 2023Article
- Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.International journal of molecular sciences · 2023Review
- Academic performance of children in relation to gender, parenting styles, and socioeconomic status: What attributes are important.PloS one · 2023Article
- Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report.The Journal of international medical research · 2021Article
- Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.Journal of immunology research · 2021Review
- Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck.World journal of clinical oncology · 2020Review
- Effect of erlotinib combined with cisplatin on IL-6 and IL-12 in mice with Lewis lung cancer.Oncology letters · 2020Article
- New pathways in immune stimulation: targeting OX40.ESMO open · 2020Article
- Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy inJournal for immunotherapy of cancer · 2020Observational
- [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30855760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.